Large pharma has been seeking new biomarkers for years â€“ all part of their drug discovery process, but often only as an afterthought in the development process. Thatâ€™s changed over recent years, but by-and-large the bulk of biomarker work remains in the hands of small -to -medium-sized companies whose focused approach is more attuned to biomarkers being a major element of a final product.
Most pharmacologists will acknowledge that nutrition is important for good health and well-being, however, at the same time it is also considered to be a chemical nightmare with unknown effects. This has not always been the case, in the past connections between pharmacology and nutrition has been more intimate, as Hippocrates once stated, â€˜â€˜Let food be thy medicine and let medicine be thy food.
Johan Garssen, PhD, Conference Chairman
Reshaping the pharmaceutical industry's quality standards is currently the top priority for the Chinese government. Earlier announcements by its Ministry of Health to issue new tougher Good Manufacturing Processes (GMP) standards for medical products comes at the right time as current regulations do not meet international standards which result in poor performance by Chinese companies in the international market.
Now more than ever, alternative science and holistic remedies are playing a role in our lifestyles. But is that right? Over the past year, we've reported on everything from homeopathy to hypnotherapy. Importantly, we've differentiated between those approaches with at least a modicum of evidence to support them, and those without almost any at all. Yet in contrast to homeopathy, perhaps it can be said that our next target has at least a little science to support it.
Last week Pharmaceutical heads met as a result of a drugs recall after a pill mix up of breast cancer pills. The drug, Fresenius Kabiâ€™s Anastrozole, was made by the German companyâ€™s subsidiary in India. The ingredient mix up led to the voluntary recall of 7,192 bottles, each containing 30 tablets.
Emma Naylor- NG Online
As Republican Congressmen line up to attack Barack Obamaâ€™s landmark U.S. healthcare reforms ahead of next monthâ€™s mid-term elections, reforms on this side of the Atlantic are receiving equally forceful criticism.
Out there on the branding battlefields its simply do or die as brand images are either hyper visible or mortally lost in oblivion. Commanding success for any idea on the global scene demands universal access on e-commerce that is only deliverable by a cyber name identity, as it's the only key to open the site.
The Kingdom of Saudi Arabia provides a new opportunity for clinical research, and can open doors to untapped populations, explains Rani Abraham at ClinTec International
Rani Abraham - ClinTec International
With access, cost and quality concerns plaguing pharmaceutical delivery systems both in the US as well as globally, the Next Generation Pharmaceutical Drug Discovery committee has been formed to confront, assess and deliver new strategies to secure the future of the industry.
If you have been looking around for a CV writing service you will have noticed that prices vary considerably and may be wondering why. The CV & Interview Advisors (thatâ€™s us) were one of the early entrants into the world of CV writing and have been around for many years.
Over the last few years, many companies have started to offer CV appraisals to the extent that the market is now flooded with offers of free advice. I remember the days when we and one or two other CV writing companies offered such a service and it became a very effective way of building relationships with customers and strutting our expertise on all things CV related.
In my capacity as a Career Consultant, I have worked closely with freelancers & contractors for many years and two challenges keep rearing their ugly head: Firstly, how does a freelancer write a CV that isnâ€™t six pages long; and secondly, what happens if you want to apply for a role that draws upon skills gained in a contract that isnâ€™t the most recent piece of work that you have done.
In a climate of fiscal hardship, everybody has a special case to plead. Indeed, when the funding scalpel is out, every department and almost every recipient of public sector funds has a special tale to tell. The truth is, science funding really is that important.
As healthcare innovation produces new treatments, and new information delivers increased awareness, a substantial rise in prescription drug use is only to be expected. For the most part, this can largely be seen as a positive development.
Potentially lifesaving science should not be marginalized to the status of a political football. Yet for so many years in the United States, thatâ€™s exactly what stem cell science has become.
Last week, leaders from companies like AstraZeneca, GlaxoSmithKline, Pfizer and Roche met in Vienna in a closed meeting to discuss the future of the pharma industry. Fears of layoffs at pharmaceutical companies are once again dominating the news, but could there be a less painful way to save money?
Even in the good years, mental health budgets were seldom in line with what experts expected or deemed necessary. Thus, in times of budget deficits and scathing public expenditure cuts, the worry becomes even greater. For those that care most about the health service then, the Coalition government's decision to ring fence healthcare spending has been largely applauded.
Originally born under the Conservatives, but fully evolved under Labour, Private Finance Initiatives (PFIs) essentially offered the NHS an alternative way of paying for new hospitals and renovations at a time when public capital was said to be limited.
While long prohibited under UK ABPI regulations, if youâ€™ve worked in the world of big pharma in the U.S., youâ€™ll have seen it all a hundred times. A drugs company sponsors a medical conference, they pay for the meals and flights of the delegates and they hand them all a goodie bag as they leave.
We have a fundamental problem with our health service. It's bloated, it's weighed down in bureaucracy and it's terribly inefficient. That's if you believe the diagnosis of our health service by the new Health Secretary, Andrew Lansley.
If the nationâ€™s recruiters received a pound for every time theyâ€™d interviewed a candidate that looked good on paper but disappointed in practice, thereâ€™d currently be an awful lot of recruiters in the process of relocating to the Caribbean.
Max Golby / Mike Wood
Back in May, it was announced that new stem cell research would reduce the need for animal testing. Now, we are really beginning to see the benefits of groundbreaking science that is not reliant on out dated methods of testing.
During a time of major economic downturn, there are few industries that can be said to be truly â€˜recession proofâ€™. Yet for years now, big pharma has largely been seen as precisely that. After all, no matter dire the markets, and no matter how low consumer confidence plummets, there is always a demand for healthcare.
In areas such as competition policy and choice in the NHS, there could be said to be much correlation between the approaches of both governments past and present. Yet in other key areas of policy, there are unquestionably examples of ideological, or at least philosophical, differences in outlook. Or at least in theory.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her